Racial, Ethnic, and Socioeconomic Disparities in Access to Transcatheter Aortic Valve Replacement Within Major Metropolitan Areas

Authors:

Abstract
Transcatheter aortic valve replacement (TAVR) transformed the management of aortic stenosis (AS) when it was approved by the US Food and Drug Administration in 2011 by expanding the population of patients eligible for life-prolonging valve replacement to include patients who were previously ineligible for surgical aortic valve replacement (SAVR).1-4 Subsequently, TAVR has been shown to offer a noninferior alternative to SAVR for patients at lower risk.5-7 However, the complexity of TAVR, along with regulatory requirements for TAVR, has led to concerns regarding inequities in access to this procedure.8-10

This publication has 28 references indexed in Scilit: